TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
20.70
-0.01 (-0.05%)
At close: 4:04PM EST

20.61 -0.09 (-0.43%)
After hours: 7:55PM EST

Stock chart is not supported by your current browser
Previous Close20.71
Open20.78
Bid0.00 x 0
Ask0.00 x 0
Day's Range20.14 - 21.25
52 Week Range10.85 - 37.94
Volume21,428,408
Avg. Volume26,902,541
Market Cap21.031B
Beta0.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-11-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • General Electric among IQ 100 laggards
    CNBC Videos7 days ago

    General Electric among IQ 100 laggards

    The CNBC IQ 100 index beating the broader market over one year up 24%. Today's leaders include Seagate, Motorola and Teva Pharma. The laggards Dexcom, Mattel and GE.

  • Generic-Drug Makers Fall as Justice Department Threatens to Sue
    Bloomberg10 hours ago

    Generic-Drug Makers Fall as Justice Department Threatens to Sue

    Shares of generic-drug makers including Mylan NV and Teva Pharmaceutical Industries Ltd. fell after the Justice Department’s antitrust division said it might sue them for damages in a price-fixing probe....

  • Generic-Drug Firms Fall as U.S. Threatens to Sue for Damages
    Bloomberg10 hours ago

    Generic-Drug Firms Fall as U.S. Threatens to Sue for Damages

    Shares of generic-drug makers including Mylan NV and Teva Pharmaceutical Industries Ltd. fell after the Justice Department’s antitrust division said it might sue them for damages in a price-fixing probe....

  • How Hospitals Plan To Put Pressure On Generic-Drug Makers
    Investor's Business Dailyyesterday

    How Hospitals Plan To Put Pressure On Generic-Drug Makers

    Generic-drug makers were hit Thursday after hospitals said they would make medicines themselves to circumvent high prices.

  • American City Business Journalsyesterday

    Teva cutting 200+ local jobs as part of broader restructuring plan

    Teva Pharmaceutical Industries will be laying off more than 200 local employees as part of a major restructuring plan designed to save the company $3 billion by the end of 2019. The Israeli generic drug maker, which calls North Wales, Pa. its U.S. headquarters, said last month it would eliminate 14,000 positions globally — more that 25 percent of its total work force — over the next two years. It has about 56,000 employees worldwide including about 2,000 people in North Wales, West Chester and Frazer, Pa.

  • Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip
    InvestorPlaceyesterday

    Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) had a very bad 2017. The government of Israel actually got involved and there were protests in the street because this was a gem of the Israeli business community. TEVA was the largest generic drug manufacturer in the U.S. And it also had a brand drug, Copaxone, that was doing well and represented about 80% of its free cash flow.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist3 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily3 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • InvestorPlace3 days ago

    Strong UnitedHealth Group Inc Earnings Keep Rally Going

    It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist3 days ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks3 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realist4 days ago

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realist4 days ago

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist4 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist4 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist5 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist5 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool6 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These three small biotech stocks saw huge jumps. Can their momentum continue?

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist7 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes
    Bloomberg7 days ago

    Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes

    Teva Pharmaceutical Industries Ltd.’s credit rating was cut into junk territory by Moody’s Investors Service, adding to the company’s woes as revenue from its bestselling drug drops and it sells assets ...

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist7 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • MarketWatch7 days ago

    Teva credit rating downgraded to junk status at Moody's

    Teva Pharmaceuticals Industries Ltd.'s credit rating was downgraded two notches into junk status at Moody's Investors Service, which cited concerns over the drug maker's sizable debt. The rating agency ...

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist7 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Moody's7 days ago

    Teva Pharmaceutical Finance Netherlands II BV -- Moody's downgrades Teva to Ba2; outlook stable

    Rating Action: Moody's downgrades Teva to Ba2; outlook stable. Global Credit Research- 12 Jan 2018. New York, January 12, 2018-- Moody's Investors Service downgraded the senior unsecured ratings of Teva ...

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist7 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.